自己免疫性消化管運動障害の世界市場レポート 2025年

自己免疫性消化管運動障害の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.9％で23億米ドルに成長します。予測期間中の成長は、自己免疫疾患の有病率の上昇、診断技術の向上、ヘルスケア支出の増加、希少疾患登録の増加、臨床医に対する教育の向上など、いくつかの要因によるものと考えられます。この時期の主な動向としては、診断技術の進歩、免疫療法の革新、神経消化器病学の研究開発、運動調節薬の研究開発、個別化治療アプローチの採用などが挙げられます。

自己免疫疾患の有病率の増加は、今後数年間の自己免疫性消化管運動障害市場の成長を促進すると予想されます。自己免疫疾患は、身体の免疫系が感染や異物から防御する代わりに、自身の健康な細胞や組織、臓器を誤って攻撃することで発生します。自己免疫疾患の増加は、主に遺伝的素因と環境要因の組み合わせに起因しており、これらの要因が相まって免疫系の調節が乱れ、身体が自身の組織を攻撃する可能性が高まります。自己免疫性消化管運動障害は、腸神経系への免疫介在性障害を明らかにし、消化器症状と全身的な自己免疫活動を関連付けることで、自己免疫疾患の基礎疾患の特定と管理に重要な役割を果たします。例えば、2024年11月にドイツを拠点とする団体Versorgungsatlas.deが実施した調査によると、2022年に調査対象となった7,324万1,305人のうち、約630万4,340人が少なくとも1つの自己免疫疾患と診断され、有病率は8.61％となりました。その結果、自己免疫疾患の有病率の上昇が自己免疫性消化管運動障害市場の成長に寄与しています。

個別化医療が重視されるようになったことで、自己免疫性消化管運動障害市場の今後の拡大が期待されます。個別化医療とは、個人固有の遺伝的体質、ライフスタイル、環境に基づいて治療や予防戦略を調整する医療アプローチを指します。個別化医療が注目されるようになった背景には、遺伝子変異の正確な特定と個別化治療の開発を可能にするゲノミクスの進歩があります。自己免疫性消化管運動障害の場合、個別化医療は個人の遺伝的体質や特定の疾患の特徴に合わせて治療法を調整することで役立ちます。このアプローチは治療効果を高めるだけでなく、副作用を最小限に抑え、複雑な消化器疾患の管理により的を絞ったソリューションを提供します。例えば、2024年2月、米国の非営利団体である個別化医療連合（PMC）は、米国食品医薬品局（FDA）が2023年に26件の個別化新薬を承認したと報告しました。したがって、個別化医療への注目の高まりが自己免疫性消化管運動障害市場の成長に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の自己免疫性消化管運動障害のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の自己免疫性消化管運動障害市場：成長率分析
• 世界の自己免疫性消化管運動障害市場の実績：規模と成長、2019～2024年
• 世界の自己免疫性消化管運動障害市場の予測：規模と成長、2024～2029年、2034年
• 世界の自己免疫性消化管運動障害総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の自己免疫性消化管運動障害市場：治療タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 薬剤
• 外科的介入
• 食事管理
• 理学療法
• 世界の自己免疫性消化管運動障害市場：薬剤クラス別、実績と予測、2019～2024年、2024～2029年、2034年
• 消化管運動促進剤
• 抗炎症薬
• 免疫抑制薬
• 抗生物質
• 世界の自己免疫性消化管運動障害市場：疾患タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 胃不全麻痺
• 慢性偽性腸閉塞（CIPO）
• 機能性消化不良
• 過敏性腸症候群（IBS）
• セリアック病
• 世界の自己免疫性消化管運動障害市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• その他
• 世界の自己免疫性消化管運動障害市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• クリニック
• 在宅ケア設定
• 研究機関
• 世界の自己免疫性消化管運動障害市場：薬剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 免疫抑制剤
• コルチコステロイド
• 消化管運動促進剤
• 制吐剤
• 鎮痙薬
• 抗生物質
• 世界の自己免疫性消化管運動障害市場：外科的介入のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 胃瘻造設術
• 空腸瘻造設術
• 結腸瘻造設術
• 回腸造設術
• 幽門形成術
• 結腸切除術
• 世界の自己免疫性消化管運動障害市場：食事管理のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 経腸栄養
• 静脈栄養
• グルテンフリーダイエット
• エレメンタルダイエット
• 少量の頻回食
• 世界の自己免疫性消化管運動障害市場：理学療法のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 骨盤底療法
• 腹部マッサージ療法
• 神経筋電気刺激（NMES）
• バイオフィードバック療法
• 呼吸筋トレーニング
• 姿勢トレーニング

第7章 地域別・国別分析

• 世界の自己免疫性消化管運動障害市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の自己免疫性消化管運動障害市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 自己免疫性消化管運動障害市場：競合情勢
• 自己免疫性消化管運動障害市場：企業プロファイル
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Chugai Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Zeria Pharmaceutical Co. Ltd.
• Ironwood Pharmaceuticals Inc.
• Vanda Pharmaceuticals Inc.
• Dr. Falk Pharma GmbH
• Rose Pharma LLC
• Parvus Therapeutics Inc.
• CinDome Pharma Inc.
• Neurogastrx Inc.
• Renexxion LLC
• ISOThrive Inc.
• Ambrose Healthcare Inc.
• AnTolRx Inc.
• Enteralia Bioscience S.r.l.
• Immunic Inc.
• Mozart Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 自己免疫性消化管運動障害市場2029年：新たな機会を提供する国
• 自己免疫性消化管運動障害市場2029年：新たな機会を提供するセグメント
• 自己免疫性消化管運動障害市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Autoimmune gastrointestinal dysmotility (AGID) is a rare condition in which the immune system attacks the nerves that control the movement of the digestive tract. This results in slowed or abnormal motility, leading to symptoms such as nausea, bloating, constipation, and intestinal blockage. AGID is often associated with autoimmune diseases or can occur as a paraneoplastic syndrome.

The main treatment options for autoimmune gastrointestinal dysmotility include medications, surgical interventions, dietary management, and physical therapy. Medications aim to manage the disorder by reducing inflammation and improving digestive tract motility. The drug classes used include prokinetic agents, anti-inflammatory drugs, immunosuppressive drugs, and antibiotics. Diseases linked to autoimmune gastrointestinal dysmotility include gastroparesis, chronic intestinal pseudo-obstruction (CIPO), functional dyspepsia, irritable bowel syndrome (IBS), and celiac disease. These drugs are distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other distribution networks. They are used by a variety of end-users, including hospitals, clinics, home care settings, and research institutions.

The autoimmune gastrointestinal dysmotility market research report is one of a series of new reports from The Business Research Company that provides autoimmune gastrointestinal dysmotility market statistics, including the autoimmune gastrointestinal dysmotility industry global market size, regional shares, competitors with the autoimmune gastrointestinal dysmotility market share, detailed autoimmune gastrointestinal dysmotility market segments, market trends, and opportunities, and any further data you may need to thrive in the autoimmune gastrointestinal dysmotility industry. This autoimmune gastrointestinal dysmotility market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The autoimmune gastrointestinal dysmotility market size has grown strongly in recent years. It will grow from $1.73 billion in 2024 to $1.83 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth during the historic period can be attributed to several factors, including increasing awareness of rare diseases, the rise in underdeveloped diagnostic practices, a growing number of misdiagnoses with other gastrointestinal disorders, the unavailability of targeted therapies, and delays in research progress.

The autoimmune gastrointestinal dysmotility market size is expected to see strong growth in the next few years. It will grow to $2.30 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth during the forecast period can be attributed to several factors, including the rising prevalence of autoimmune diseases, improvements in diagnostic techniques, increasing healthcare expenditure, the growth of rare disease registries, and better education for clinicians. Key trends during this period include technological advancements in diagnostics, innovations in immunotherapy, developments in neurogastroenterology research, research and development in motility modulators, and the adoption of personalized treatment approaches.

The increasing prevalence of autoimmune disorders is expected to drive the growth of the autoimmune gastrointestinal dysmotility market in the coming years. Autoimmune diseases occur when the body's immune system mistakenly attacks its own healthy cells, tissues, or organs, instead of defending them from infections and foreign substances. The rise in autoimmune disorders is mainly attributed to a combination of genetic predisposition and environmental factors, which together disrupt immune system regulation and increase the likelihood of the body attacking its own tissues. Autoimmune gastrointestinal dysmotility plays a key role in identifying and managing underlying autoimmune conditions by revealing immune-mediated damage to the enteric nervous system, linking gastrointestinal symptoms to systemic autoimmune activity. For example, in November 2024, a survey conducted by Versorgungsatlas.de, a Germany-based organization, showed that out of 73,241,305 people surveyed in 2022, around 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61. As a result, the rising prevalence of autoimmune disorders is contributing to the growth of the autoimmune gastrointestinal dysmotility market.

The growing emphasis on personalized medicine is expected to drive the expansion of the autoimmune gastrointestinal dysmotility market moving forward. Personalized medicine refers to a medical approach that tailors treatment and prevention strategies based on an individual's unique genetic makeup, lifestyle, and environment. The increasing prominence of personalized medicine is largely driven by advancements in genomics, which enable the precise identification of genetic variations and the development of customized treatments. In the case of autoimmune gastrointestinal dysmotility, personalized medicine helps by tailoring therapies to the individual's genetic makeup and specific disease characteristics. This approach not only enhances treatment efficacy but also minimizes side effects, offering more targeted solutions for managing complex gastrointestinal disorders. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a notable increase from the 12 approved in 2022. Therefore, the increasing focus on personalized medicine is contributing to the growth of the autoimmune gastrointestinal dysmotility market.

Key players in the autoimmune gastrointestinal dysmotility market are focusing on forming strategic partnerships to offer digital therapy solutions for managing autoimmune gastrointestinal dysmotility conditions. Strategic partnerships improve care for autoimmune gastrointestinal dysmotility by providing integrated, virtual-first healthcare with multidisciplinary teams, enhancing symptom management, improving access to care, and increasing cost efficiency. For example, in March 2022, Solera Health, a US-based digital health company, partnered with Oshi Health, a US-based virtual gastrointestinal care company, and Vivante Health, a US-based digital health company. This collaboration aims to deliver advanced digital therapy solutions to support the management and treatment of autoimmune gastrointestinal dysmotility. The partnership focuses on improving patient access to specialized care and enhancing the overall effectiveness of treatments for individuals with gastrointestinal disorders.

Major players in the autoimmune gastrointestinal dysmotility market are AbbVie Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Zeria Pharmaceutical Co. Ltd., Ironwood Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Dr. Falk Pharma GmbH, Rose Pharma LLC, Parvus Therapeutics Inc., CinDome Pharma Inc., Neurogastrx Inc., Renexxion LLC, ISOThrive Inc., Ambrose Healthcare Inc., AnTolRx Inc., Enteralia Bioscience S.r.l., Immunic Inc., Mozart Therapeutics Inc.

North America was the largest region in the autoimmune gastrointestinal dysmotility market in 2024. The regions covered in autoimmune gastrointestinal dysmotility report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the autoimmune gastrointestinal dysmotility market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The autoimmune gastrointestinal dysmotility market consists of revenues earned by entities by providing services such as diagnostic testing, therapeutic treatments, clinical consultations, surgical interventions, rehabilitation and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The autoimmune gastrointestinal dysmotility market also includes sales of diagnostic kits, immunomodulatory drugs, prokinetic agents, and intravenous immunoglobulin (IVIG) therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Autoimmune Gastrointestinal Dysmotility Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on autoimmune gastrointestinal dysmotility market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for autoimmune gastrointestinal dysmotility ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The autoimmune gastrointestinal dysmotility market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Medications; Surgical Interventions; Dietary Management; Physical Therapy
• 2) By Drug Class: Prokinetic Agents; Anti-Inflammatory Drugs; Immunosuppressive Drugs; Antibiotics
• 3) By Disease Type: Gastroparesis; Chronic Intestinal Pseudo-Obstruction (Cipo); Functional Dyspepsia; Irritable Bowel Syndrome (Ibs); Celiac Disease
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacies; Other Distribution Channels
• 5) By End User: Hospitals; Clinics; Home Care Settings; Research Institutions
• Subsegments:
• 1) By Medications: Immunosuppressants; Corticosteroids; Prokinetic Agents; Antiemetics; Antispasmodics; Antibiotics
• 2) By Surgical Interventions: Gastrostomy; Jejunostomy; Colostomy; Ileostomy; Pyloroplasty; Colectomy
• 3) By Dietary Management: Enteral Nutrition; Parenteral Nutrition; Gluten-Free Diet; Elemental Diet; Small Frequent Meals
• 4) By Physical Therapy: Pelvic Floor Therapy; Abdominal Massage Therapy; Neuromuscular Electrical Stimulation (NMES); Biofeedback Therapy; Respiratory Muscle Training; Postural Training
• Companies Mentioned: AbbVie Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.; Chugai Pharmaceutical Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Autoimmune Gastrointestinal Dysmotility Market Characteristics

3. Autoimmune Gastrointestinal Dysmotility Market Trends And Strategies

4. Autoimmune Gastrointestinal Dysmotility Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Autoimmune Gastrointestinal Dysmotility Growth Analysis And Strategic Analysis Framework

• 5.1. Global Autoimmune Gastrointestinal Dysmotility PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Autoimmune Gastrointestinal Dysmotility Market Growth Rate Analysis
• 5.4. Global Autoimmune Gastrointestinal Dysmotility Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Autoimmune Gastrointestinal Dysmotility Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Autoimmune Gastrointestinal Dysmotility Total Addressable Market (TAM)

6. Autoimmune Gastrointestinal Dysmotility Market Segmentation

• 6.1. Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medications
• Surgical Interventions
• Dietary Management
• Physical Therapy
• 6.2. Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prokinetic Agents
• Anti-Inflammatory Drugs
• Immunosuppressive Drugs
• Antibiotics
• 6.3. Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gastroparesis
• Chronic Intestinal Pseudo-Obstruction (Cipo)
• Functional Dyspepsia
• Irritable Bowel Syndrome (Ibs)
• Celiac Disease
• 6.4. Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Other Distribution Channels
• 6.5. Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Home Care Settings
• Research Institutions
• 6.6. Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunosuppressants
• Corticosteroids
• Prokinetic Agents
• Antiemetics
• Antispasmodics
• Antibiotics
• 6.7. Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Surgical Interventions, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gastrostomy
• Jejunostomy
• Colostomy
• Ileostomy
• Pyloroplasty
• Colectomy
• 6.8. Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Dietary Management, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enteral Nutrition
• Parenteral Nutrition
• Gluten-Free Diet
• Elemental Diet
• Small Frequent Meals
• 6.9. Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Physical Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pelvic Floor Therapy
• Abdominal Massage Therapy
• Neuromuscular Electrical Stimulation (NMES)
• Biofeedback Therapy
• Respiratory Muscle Training
• Postural Training

7. Autoimmune Gastrointestinal Dysmotility Market Regional And Country Analysis

• 7.1. Global Autoimmune Gastrointestinal Dysmotility Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Autoimmune Gastrointestinal Dysmotility Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Autoimmune Gastrointestinal Dysmotility Market

• 8.1. Asia-Pacific Autoimmune Gastrointestinal Dysmotility Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Autoimmune Gastrointestinal Dysmotility Market

• 9.1. China Autoimmune Gastrointestinal Dysmotility Market Overview
• 9.2. China Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Autoimmune Gastrointestinal Dysmotility Market

• 10.1. India Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Autoimmune Gastrointestinal Dysmotility Market

• 11.1. Japan Autoimmune Gastrointestinal Dysmotility Market Overview
• 11.2. Japan Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Autoimmune Gastrointestinal Dysmotility Market

• 12.1. Australia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Autoimmune Gastrointestinal Dysmotility Market

• 13.1. Indonesia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Autoimmune Gastrointestinal Dysmotility Market

• 14.1. South Korea Autoimmune Gastrointestinal Dysmotility Market Overview
• 14.2. South Korea Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Autoimmune Gastrointestinal Dysmotility Market

• 15.1. Western Europe Autoimmune Gastrointestinal Dysmotility Market Overview
• 15.2. Western Europe Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Autoimmune Gastrointestinal Dysmotility Market

• 16.1. UK Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Autoimmune Gastrointestinal Dysmotility Market

• 17.1. Germany Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Autoimmune Gastrointestinal Dysmotility Market

• 18.1. France Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Autoimmune Gastrointestinal Dysmotility Market

• 19.1. Italy Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Autoimmune Gastrointestinal Dysmotility Market

• 20.1. Spain Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Autoimmune Gastrointestinal Dysmotility Market

• 21.1. Eastern Europe Autoimmune Gastrointestinal Dysmotility Market Overview
• 21.2. Eastern Europe Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Autoimmune Gastrointestinal Dysmotility Market

• 22.1. Russia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Autoimmune Gastrointestinal Dysmotility Market

• 23.1. North America Autoimmune Gastrointestinal Dysmotility Market Overview
• 23.2. North America Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Autoimmune Gastrointestinal Dysmotility Market

• 24.1. USA Autoimmune Gastrointestinal Dysmotility Market Overview
• 24.2. USA Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Autoimmune Gastrointestinal Dysmotility Market

• 25.1. Canada Autoimmune Gastrointestinal Dysmotility Market Overview
• 25.2. Canada Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Autoimmune Gastrointestinal Dysmotility Market

• 26.1. South America Autoimmune Gastrointestinal Dysmotility Market Overview
• 26.2. South America Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Autoimmune Gastrointestinal Dysmotility Market

• 27.1. Brazil Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Autoimmune Gastrointestinal Dysmotility Market

• 28.1. Middle East Autoimmune Gastrointestinal Dysmotility Market Overview
• 28.2. Middle East Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Autoimmune Gastrointestinal Dysmotility Market

• 29.1. Africa Autoimmune Gastrointestinal Dysmotility Market Overview
• 29.2. Africa Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Autoimmune Gastrointestinal Dysmotility Market Competitive Landscape And Company Profiles

• 30.1. Autoimmune Gastrointestinal Dysmotility Market Competitive Landscape
• 30.2. Autoimmune Gastrointestinal Dysmotility Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Chugai Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Autoimmune Gastrointestinal Dysmotility Market Other Major And Innovative Companies

• 31.1. Zeria Pharmaceutical Co. Ltd.
• 31.2. Ironwood Pharmaceuticals Inc.
• 31.3. Vanda Pharmaceuticals Inc.
• 31.4. Dr. Falk Pharma GmbH
• 31.5. Rose Pharma LLC
• 31.6. Parvus Therapeutics Inc.
• 31.7. CinDome Pharma Inc.
• 31.8. Neurogastrx Inc.
• 31.9. Renexxion LLC
• 31.10. ISOThrive Inc.
• 31.11. Ambrose Healthcare Inc.
• 31.12. AnTolRx Inc.
• 31.13. Enteralia Bioscience S.r.l.
• 31.14. Immunic Inc.
• 31.15. Mozart Therapeutics Inc.

32. Global Autoimmune Gastrointestinal Dysmotility Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Autoimmune Gastrointestinal Dysmotility Market

34. Recent Developments In The Autoimmune Gastrointestinal Dysmotility Market

35. Autoimmune Gastrointestinal Dysmotility Market High Potential Countries, Segments and Strategies

• 35.1 Autoimmune Gastrointestinal Dysmotility Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Autoimmune Gastrointestinal Dysmotility Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Autoimmune Gastrointestinal Dysmotility Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer